While glycolysis is vitally essential metabolism for energy production in cells, its enhancement is frequently observed in cancers, known as the Warburg effect. Although the importance of the Warburg effect is clinically defined, it is still not clear how the Warburg effect is coupled to the other cancerous hallmark, e.g. immortalization. Glycolysis would be dysregulated in cancers, which is supported by recent findings on their transcriptional regulation. But among others, phosphoglycerate mutase, PGAM, is an outlier, as the heavy posttranscriptional regulation is operating for it. Here we review about the posttranscriptional regulation of PGAM, especially its ubiquitination by Mdm2 as we reported recently.
Introduction
Compared to normal tissues, enhanced glycol sis is well-known metabolic characteristics observed in many cancers, called as the Warburg effect. The protein levels and enzymatic activities of many glycolytic enzymes are also enhanced in cancer. Its impact in cancer is well defined, as FDG-PET is utilized to detect the origin and metastatic lesions in cancer patients, for example. Thus glycolytic pathway is dysregulated in cancer cells.
Cytological hallmarks of cancer cells are listed as several properties; immortalization, evasion from apoptotic stimuli, metastatic capacity, anchorage-independent growth, and so on. Some of these properties could be coupled with any cancerous metabolisms, such as the Warburg effect. Recent studies suggest the causal effects of enhanced glycol sis on cancerous growth; (1) antioxidant effect via reduction in mitochondrial respiration [1] or pentose phosphate pathway (PPP) activation [2] , (2) biomass synthesis, (3) resistance to senescence-inducing stress [3] .
Normal primary cells display the limitation of proliferative capacity under standard culture conditions, and eventually undergo irreversible cell cycle arrest with telomeric erosion after serial passages, designated as replicative senescence [4] . In addition, any senescence-inducing stress, including oxidative stress, DNA damage, and oncogenic insult, triggers
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premature senescence in primary cells with long intact telomere [5] . During senescence process, the decline of glycolysis was observed in human and mouse primary cells. Recent report suggests that glycolytic modulation via ectopic expression of its component make cells escape from senescence-inducing effect and immortalize them [3, 6] Collectively, in cancers, the glycolysis is greatly dysregulated, but closely coupled with their hallmarks. Now the rising question is how the glycolysis is regulated and dysregulated in normal and cancer cells, respectively.
The significance of PGAM in the Warburg effect
Phosphoglycerate mutase PGAM is a glycolytic enzyme, which catalyses the conversion of 3-phosphoglycerate into 2-phosphoglycerate. Two isoforms of PGAM, PGAM-1 and -2, share great identity in protein sequence (78.7% in human, 80.7% in mouse), with almost similar enzymatic activity. Expression profile of PGAM-1 and -2 are variable among tissues. It was found that PGAM2 mRNA levels are almost equivalent to or exceed PGAM1 mRNA levels in some mouse tissues (skin, bone and lung), while PGAM1 mRNA is predominant in others (blood vessel, white adipose tissue, liver) [7] .
Recent several lines of evidence implicate the significance of PGAM on cancerous proliferation; chemical screening identified MJE3, inhibitor of PGAM, as most potent anti-cancer drug against breast cancer cells [8] , while cancer specific glycolytic enzyme PKM2 activate alternative glycolytic pathway in cancer by activating PGAM [9] . Our group previously identified PGAM as an immortalizing clone in mouse fibroblast (MEFs) by using cDNA library [3] .
Thus there is no argue about the significant impact of PGAM on cancer growth, and now the regulatory mechanism of PGAM would be keen interests for cancer researchers.
It is possible that the Warburg effect would be the consequence of any cellular adaptation during tumorigenesis. For example, HIF-1 (hypoxia-inducible transcription factor 1) is required to upregulate many glycolytic enzymes under hypoxic conditions, which could be closely relevant to the condition of tumor in vivo [10] . But the Warburg effect could not be simply explained as the adaptation to hypoxic condition in vivo, for following reasons. First, cancer cells maintain highly glycolytic feature even in tissue culture condition under normoxia (20%) and in circulating blood [11] . Second, the ectopic expression of HIF-1 cause cell cycle arrest in some cell lines [12] . Third, cancerous growth and its glycolysis are not affected by HIF-1 knock down in some cell types [13] . Forth, PGAM, a key in cancer proliferation, is the only exception which is not subject to regulation of HIF-1 [10] .
There are also other reports on the regulation of several glycolytic enzymes by transcriptional factor except HIF-1. Oncogene c-Myc also positively regulates several glycolytic enzymes, including PFK, Enolase and Glut1 [14] . Noteworthy, less reports are described about transcriptional regulation of PGAM [15] . Tumor suppressor p53 positively regulated PGAM in muscle, while others are negatively regulated by p53 [16] . Thus, PGAM could be differently regulated in cancer, compared to others. Indeed now it is found that the heavy posttranscriptional regulation is operating for PGAM.
Posttranscriptional regulation for PGAM
Historically, Tony Hunter and his colleagues first reported the phosphorylation of PGAM in cells transformed by Rous sarcoma virus [17] . Shalom-Barak et al also reported that p21cdc42/Rac1-activated kinase1, Pak1, phosphorylates PGAM on its serine residue 118 in cancer cell line HEK293T, followed by the downregulation of its enzymatic activity [18] . Pak1 is known to be involved in many cellular processes, such as cell motility, the cytoskeleton reorganization, apoptosis and cancer. Moreover recent reports suggest oncogenic tyrosine kinase also phosphorylates PGAM [19] .
Recently we discovered that PGAM is regulated by ubiquitin/proteasome pathway during senescence process [7] . We observed in primary MEFs that under DNA damage or oncogenic stress (ectopic expression of oncogenic Ras-G12V), the protein level and enzymatic activity of PGAM is remarkably decreased, accompanied with the decline of glycolytic flux. The downregulation of PGAM protein is mainly due to its ubiquitination and degradation, not due to the transcriptional regulation.
The ubiquitination of many proteins is known to require the advanced modifications of substrates, e.g. phosphorylation. We suspect Pak1 kinase as priming kinase for the ubiquitination of PGAM, although previous work suggested that Pak1 did not affect the protein level of PGAM in HEK293T cells. Indeed, Pak1 overexpression in primary MEFs provokes premature senescence, accompanied with the ubiquitination and degradation of PGAM. Moreover, senescence-inducing stress activates Pak1 protein, followed by phosphorylation of PGAM in its serine 118 residue. On the other hand, the ablation of phosphorylation for PGAM by Pak1 restored the stability of PGAM. These findings suggest that in stress-induced senescent cells, phosphorylation of PGAM by Pak1 promotes its degradation.
Mdm2 is an ubiquitin ligase for PGAM
Three enzymes are required for the process of ubiquitination; E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase). E3 is very specific for its substrate, while E1 and E2 share many target proteins. We noticed that PGAM protein level was affected by p53 status. And finally we found that RING ubiquitin ligase Mdm2, downstream of p53, promotes the ubiquitination of PGAM. Mdm2 binds to PGAM strongly under stress in a Pak1-dependent manner. Ubiquitination reaction of PGAM by Mdm2 in vitro was also observed. This was the first report on the effect of Mdm2 on the ubiquitination of glycolytic enzyme.
Mdm2 mutant, defective for PGAM ubiquitination promotes neoplasmic transformation
Mdm2 has been considered as oncogene for following reasons. [20] . The double-edged sword behavior of Mdm2 remained a mystery.
To dissect the dual role of Mdm2 as oncogene and tumor suppressor, we explored oncogenic mutations of Mdm2 in the comprehensive database discovered in cancer samples. We noticed three new Mdm2 mutations, Y281H, W329G, and M459I. Interestingly, these three mutants effectively inactivated p53 transactivation like wild type does, whereas their ability for PGAM ubiquitination was diverse. Mdm2 in RING domain variation（M459I）showed a notable decline in its ability. Consistently Mdm2-M459I enforced Ras-G12V+PGAM-TG MEFs to transform and to produce subcutaneous tumors in the nude mice.
In summary, Mdm2 displays the opposite activity toward two different substrates （ p53 and PGAM ） in cellular-context dependent manner. Under senescence inducing stress condition, p53 is stabilized, while PGAM is ubiquitinated by Mdm2. But in the presence of certain oncogenic signals, Ras-G12V and Mdm2-M459I, p53 is disabled and PGAM is stabilized, followed by enhanced glycolysis; that is the Warburg effect.
Conclusion
We disclosed several unknown aspects of PGAM regulation; (1) By senescence-inducing stress, PGAM is ubiquitinated. (2) Phosphorylation of PGAM by Pak1 kinase promotes the ubiquitination. (3) Mdm2 is an ubiquitin ligase for PGAM. (4) Mdm2-M459I stabilizes PGAM and contributes to the Warburg effect and neoplasmic transformation. Thus, cellular senescence is coupled with the Warburg effect partly by molecular interaction between Mdm2 and PGAM.
